SCHEMBL3539715

SCHEMBL3539715

COCc1cccc2[nH]nc(-c3nc4ccc(N5CCN(C)CC5)cc4[nH]3)c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 11/20 0.66
FLT1 P17948 4/20 0.66
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 2/20 0.56
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
CDK4 P11802 1/20 0.54
CCNA2 P20248 1/20 0.54
CCND1 P24385 1/20 0.54
CDK2 P24941 1/20 0.54
CCND3 P30281 1/20 0.54
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
BLM P54132 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
TOP1 P11387 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535489 0.91 FGFR1 (0.62) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3534873 0.89 FGFR1 (0.62) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3545063 0.87 FGFR1 (0.68) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3535708 0.86 FGFR1 (0.68) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3537944 0.85 FGFR1 (0.72) FGFR1FLT1KDR
SCHEMBL31006247 0.84 FGFR1 (0.71) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3533576 0.84 FGFR1 (0.71) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3541772 0.83 FGFR1 (0.74) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3537272 0.83 FGFR1 (0.71) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL5866750 0.83 FGFR1 (0.71) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ALDH1A1 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.